Jim Cramer on Merck & Co (MRK): ‘I’ve Got To Take a Hard Look At It’

Jim Cramer in a recent program on CNBC commented on Merck & Co Inc. earnings results and said the pharma giant’s report was among a series of statements from major companies that were “disappointing.”

“This is an earning season so far where a lot of the big ones that look like they’re just shockingly bad or disappointing—everyone knew. I mean, Merck reported a quarter, I think we all kind of knew that Keytruda had slowed down a little bit. We knew that there were some Gardasil problems.Winrevair, drug that they bought—pulmonary arterial hypertension—I thought it was terrific, 280 million. So I think that this is an example where you can just say, oh my god, damn, Merck down almost 40%. I got to—I, I, I got to take a hard look at it.”

Jim Cramer on Merck & Co (MRK): ‘I’ve Got To Take a Hard Look At It’

GreensKeeper Asset Management stated the following regarding Merck & Co., Inc. in its Q3 2024 investor letter:

“Merck & Co., Inc. (NYSE:MRK) was our second-largest detractor this quarter, declining -8.3%. MRK’s leading HPV vaccine, GARDASIL 9, faced challenges internationally due to inventory buildup within its Chinese distributor, which is expected to reduce shipments for the remainder of 2024. Despite this short-term impact, the long-term outlook for GARDASIL 9 remains promising. Meanwhile, the company’s $27 billion Keytruda cancer juggernaut continues to grow at a healthy clip, powering earnings growth.”

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

This article is originally published at Insider Monkey.